声动力疗法抑制NLRP3炎症小体上调CACNA1C降低房颤易感性
该研究采用脂多糖刺激的小鼠和HL-1心房肌细胞模型,探讨声动力疗法(SDT)对炎症相关心房颤动易感性的作用及机制。结果显示SDT通过抑制NLRP3炎症小体激活、上调L型钙通道CACNA1C亚基表达,降低小鼠房颤诱发率和持续时间,且该效应依赖活性氧。
要点
- SDT降低LPS刺激小鼠的房颤诱发率并缩短持续时间。
- SDT抑制心房肌细胞NLRP3炎症小体活化并上调CACNA1C表达。
- SDT的调控作用依赖活性氧,可被NAC阻断。
核心结论
- SDT通过抑制心房肌细胞NLRP3炎症小体激活、上调CACNA1C表达,降低小鼠房颤易感性。
研究设计与样本
- 采用LPS刺激的小鼠在体模型和HL-1小鼠心房肌细胞炎症模型。
- 在体实验分对照组、LPS组、LPS+SDT组和SDT组,每组20只小鼠。
- 体外实验分对照组、LPS组、LPS+SDT组、LPS+华卟啉钠组和LPS+超声组,并设NLRP3质粒转染及MCC950验证分组。
主要发现
- LPS+SDT组小鼠房颤诱发率低于LPS组、持续时间短于LPS组(P均<0.05)。
- LPS+SDT组小鼠心房NLRP3和IL-1β蛋白表达低于LPS组(P均<0.05),CACNA1C表达有升高趋势(P>0.05)。
- 体外LPS+SDT组或NLRP3质粒+SDT组NLRP3、ASC、Cleaved Caspase-1、IL-1β、IL-18表达更低,CACNA1C mRNA和蛋白更高(P均<0.05)。
- LPS+MCC950组CACNA1C蛋白表达高于LPS组(P<0.05)。
- SDT后细胞内活性氧水平升高,NAC可阻断SDT对NLRP3和CACNA1C的调控作用。
关键数值与推荐
- LPS安全给药浓度≤20 μg/ml,最佳促炎浓度4 μg/ml。
- 华卟啉钠安全给药浓度0.4 μmol/L,最佳孵育时间4 h。
临床怎么用
- 提示SDT可能通过ROS-NLRP3-CACNA1C轴减轻炎症相关房颤易感性,为房颤抗炎干预提供实验依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effect and underlying mechanism of sonodynamic therapy (SDT) on inflammation-related atrial fibrillation (AF) susceptibility. Methods: Lipopolysaccharide (LPS)-stimulated mouse and HL-1 mouse atrial myocyte models were used. (1) In vivo study: experimental groups included control, LPS, LPS+SDT, and SDT groups, with 20 mice in each group. Atrial fibrillation inducibility and duration were assessed by electrical stimulation. Western blot was used to analyze atrial expression of NOD-like receptor family pyrin domain-containing protein 3 (NLRP3), interleukin (IL)-1β, and IL-18. Immunohistochemistry was used to detect calcium voltage-gated channel subunit alpha1 C (CACNA1C) expression. (2) In vitro study: cell counting kit-8 (CCK-8) and Western blot were used to determine the optimal and safe LPS concentration. The safe incubation condition for the sonosensitizer sinoporphyrin sodium was determined by CCK-8 and fluorometry. An LPS-induced inflammatory model in HL-1 atrial myocytes was used, with experimental groups including control, LPS, LPS+SDT, LPS+sinoporphyrin sodium, and LPS+ultrasound groups. NLRP3 was overexpressed using plasmid transfection, with experimental groups including control, NLRP3 plasmid, negative control plasmid, and NLRP3 plasmid+SDT groups. SDT was applied to LPS-stimulated or NLRP3-overexpressing HL-1 cells. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were used to measure mRNA and protein levels of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), Cleaved Caspase-1, IL-1β, IL-18, and CACNA1C. The NLRP3 inhibitor MCC950 was used to validate the relationship of NLRP3 and CACNA1C. The experimental groups included control, LPS, LPS+MCC950, and MCC950 groups. Intracellular reactive oxygen species (ROS) levels were detected using the probe DCFH-DA, and the ROS scavenger N-acetyl-L-cysteine (NAC) was used to test if the effects of SDT was ROS-dependent. Results: (1) In vivo: The LPS+SDT group exhibited a lower incidence of atrial fibrillation induction and a shorter duration of atrial fibrillation compared to the LPS group(both P<0.05). Protein expression levels of NLRP3 and IL-1β were lower than those in the LPS group (all P<0.05), while the expression of CACNA1C subunit tended to increase relative to the LPS group (P>0.05). (2) In vitro: The safe concentration of LPS for administration was ≤20 μg/ml, with an optimal pro-inflammatory concentration of 4 μg/ml. The safe concentration of sinoporphyrin sodium for administration was 0.4 μmol/L, with an optimal incubation time of 4 hours. Compared to the LPS group or NLRP3 plasmid group, the LPS+SDT group or NLRP3 plasmid+SDT group exhibited lower expression levels of NLRP3, ASC, Cleaved Caspase-1, IL-1β, and IL-18, and higher mRNA and protein levels of CACNA1C (all P<0.05). The LPS+MCC950 group had higher CACNA1C protein expression than the LPS group (P<0.05). SDT increased intracellular ROS levels, and NAC blocked the regulatory effects of SDT on NLRP3 and CACNA1C. Conclusion: SDT reduces atrial fibrillation susceptibility in mice by inhibiting NLRP3 inflammasome activation in atrial cardiomyocytes, thereby upregulating the L-type calcium channel subunit CACNA1C. 目的: 探索声动力疗法(SDT)对炎症导致的心房颤动易感性增加的作用及机制。 方法: 采用脂多糖刺激小鼠和HL-1小鼠心房肌细胞系模型,(1)体内研究:将小鼠分为对照组、脂多糖组、脂多糖+SDT组和SDT组,每组20只。通过电刺激诱发心房颤动实验检测小鼠心房颤动诱发率和持续时间;Western blot检测小鼠心房NOD样受体家族含pyrin结构域蛋白3(NLRP3)、白细胞介素(IL)-1β和IL-18的表达水平;免疫组织化学染色检测小鼠心房钙电压门控通道亚基α1C(CACNA1C)的表达。(2)体外研究:通过细胞计数试剂盒法和Western blot确定脂多糖的使用浓度;细胞计数试剂盒法和荧光酶标仪检测确定声敏剂华卟啉钠的孵育条件。使用脂多糖诱导HL-1心房肌细胞炎症模型,根据干预方法将细胞分为对照组、脂多糖组、脂多糖+SDT组、脂多糖+华卟啉钠组和脂多糖+超声组。使用质粒转染技术过表达NLRP3,实验分组为对照组、NLRP3质粒组、阴性质粒组、NLRP3质粒+SDT组。采用实时荧光定量聚合酶链反应和Western blot检测NLRP3、含CARD结构的凋亡相关斑点样蛋白、活性天冬氨酸特异性的半胱氨酸蛋白水解酶1、IL-1β、IL-18和CACNA1C亚基的mRNA和蛋白表达。使用NLRP3抑制剂MCC950验证NLRP3和CACNA1C的关系,实验分组为对照组、脂多糖组、脂多糖+MCC950组和MCC950组。使用活性氧探针DCFH-DA检测细胞活性氧水平,并加入活性氧清除剂N-乙酰-L-半胱氨酸验证SDT的作用是否依赖活性氧。 结果: (1)体内研究:脂多糖+SDT组小鼠的心房颤动诱发率低于脂多糖组,且心房颤动持续时间短于脂多糖组(P均<0.05);NLRP3和IL-1β蛋白表达均低于脂多糖组(P均<0.05),CACNA1C亚基表达有高于脂多糖组的趋势(P>0.05)。(2)体外研究:脂多糖的安全给药浓度≤20 μg/ml,最佳促炎浓度为4 μg/ml;华卟啉钠的安全给药浓度为0.4 μmol/L,最佳孵育时间4 h。与脂多糖组或NLRP3质粒组相比,脂多糖+SDT组或NLRP3质粒+SDT组的NLRP3、含CARD结构的凋亡相关斑点样蛋白、活性天冬氨酸特异性的半胱氨酸蛋白水解酶1、IL-1β和IL-18表达水平均更低,CACNA1C亚基的mRNA和蛋白水平更高(P均<0.05)。脂多糖+MCC950组的CACNA1C蛋白表达水平高于脂多糖组(P<0.05)。SDT后细胞内活性氧水平升高,N-乙酰-L-半胱氨酸可阻断SDT对NLRP3和CACNA1C的调控作用。 结论: SDT通过抑制心房肌细胞NLRP3炎症小体上调L型钙通道CACNA1C亚基表达降低小鼠心房颤动易感性。.
引用
- Wang W, Wang YM, Cui HW, et al. [Inhibition of NLRP3 inflammasome by sonodynamic therapy mediates CACNA1C upregulation to reduce atrial fibrillation susceptibility]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 41287293. doi:10.3760/cma.j.cn112148-20250717-00517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。